Coya Therapeutics, Inc.
NASDAQ:COYABiotechnology
-$0.16 today
- Market cap
- $72.48M
- Beta
- 0.62
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.26
Volume 0.15M
Average 0.16M
COYA Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Coya Therapeutics, Inc.NASDAQ: COYA
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue declines year over year
Q1 FY2026 cost of revenue of $2.81K fell 99.9% year over year, in line with the -99.9% change in trailing-twelve-month cost of revenue. Over 3 fiscal years it compounded at -81.6% a year.
Context
- Cost of revenue amounted to 0.3% of revenue in FY2025, down 333.5 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -99.9% toward the trailing-twelve-month pace of -99.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 27.36K USD
- Year-over-year change
- -99.8%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27.36K | -99.8% |
| FY2024 | 2024-12-31 | 11.87M | +115.7% |
| FY2023 | 2023-12-31 | 5.5M | +24.7% |
| FY2022 | 2022-12-31 | 4.41M | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How COYA compares with its peers on the latest reported figures
- COYA's LTM Mar 2026 cost of revenue of $16.49K is the 10th highest of the 11 companies compared; the peer median is $140.88K.
- Its year-over-year change of -99.9% is the 6th highest of 7, against a peer median of -27.3%.
- Cost of revenue amounts to 0.2% of revenue for COYA, versus a peer median of 106.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $47.23M | -18.4% | +80.2% | 30.1% | |
| LTM Mar 2026 | $1.82M | -36.2% | — | 182.0% | |
| LTM Mar 2026 | $711K | +14.3% | — | — | |
| LTM Mar 2026 | $378K | +410.8% | +18.3% | 282.1% | |
| LTM Mar 2026 | $151K | — | — | — | |
| LTM Mar 2026 | $130.77K | — | — | — | |
| LTM Mar 2026 | $40.17K | — | — | — | |
| LTM Mar 2026 | $35K | — | — | 0.5% | |
| LTM Mar 2026 | $31K | -98.5% | — | — | |
| LTM Mar 2026 | $16.49K | -99.9% | -81.6% | 0.2% | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $5K | -100.0% | -71.8% | — |
| Peer median (excluding COYA) | $140.88K | -27.3% | +18.3% | 106.0% | |
Competitors are the stored peer set for COYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 6M | 3.55M | 7.95M |
| Cost of Revenue | 0 | 4.41M | 5.5M | 11.87M | 27.36K |
| Gross Profit | 0 | (4.41M) | 500.68K | (8.31M) | 7.92M |
| Gross Margin | — | — | 8.3% | -233.9% | 99.7% |
| Research & Development | 2.54M | 4.94M | 6.04M | 11.89M | 16.73M |
| Selling, General & Admin | 2.31M | 4.85M | 7.83M | 8.89M | 11.45M |
| Operating Expenses | 4.87M | 5.4M | 8.4M | 8.94M | 28.18M |
| Depreciation & Amortization | 16.13K | 27.36K | 27.36K | 27.36K | 27.36K |
| EBITDA | (4.88M) | (9.26M) | (7.33M) | (17.2M) | (21.2M) |
| EBITDA Margin | — | — | -122.2% | -483.9% | -266.8% |
| Operating Income | (4.87M) | (9.81M) | (7.9M) | (17.25M) | (20.27M) |
| Operating Margin | — | — | -131.7% | -485.4% | -255.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (21.48K) | (2.43M) | 639.37K | 1.65M | (957.4K) |
| Income Before Tax | (4.89M) | (12.24M) | (7.26M) | (15.6M) | (21.22M) |
| Pre-Tax Margin | — | — | -121.0% | -439.0% | -267.1% |
| Income Tax Expense | 0 | 0 | 723.85K | (720.29K) | 3.09K |
| Net Income | (4.89M) | (12.24M) | (7.99M) | (14.88M) | (21.23M) |
| Net Margin | — | — | -133.1% | -418.7% | -267.1% |
| EPS (Basic) | (0.74) | (1.23) | (0.79) | (0.98) | (1.27) |
| EPS (Diluted) | (0.74) | (1.23) | (0.79) | (0.98) | (1.27) |
| Weighted Avg Shares | 6.6M | 9.95M | 10.16M | 15.24M | 16.73M |
| Weighted Avg Shares (Diluted) | 6.6M | 9.95M | 10.16M | 15.24M | 16.73M |
Coya Therapeutics, Inc.
NASDAQ:COYA
Intrinsic Alpha fair value
Locked
Current Price
$3.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.